Brainstorm Cell Therapeutics (NASDAQ:BCLI) Now Covered by Analysts at StockNews.com

StockNews.com began coverage on shares of Brainstorm Cell Therapeutics (NASDAQ:BCLI) in a research note published on Wednesday morning. The brokerage issued a sell rating on the biotechnology company’s stock.

Brainstorm Cell Therapeutics Stock Performance

BCLI opened at $0.43 on Wednesday. Brainstorm Cell Therapeutics has a twelve month low of $0.13 and a twelve month high of $3.34. The firm has a market cap of $29.39 million, a price-to-earnings ratio of -1.05 and a beta of 0.40. The firm’s 50-day simple moving average is $0.49 and its 200-day simple moving average is $0.35.

Brainstorm Cell Therapeutics (NASDAQ:BCLI) last released its quarterly earnings results on Monday, April 1st. The biotechnology company reported ($0.11) earnings per share for the quarter, beating analysts’ consensus estimates of ($0.15) by $0.04. As a group, sell-side analysts anticipate that Brainstorm Cell Therapeutics will post -0.28 EPS for the current fiscal year.

Institutional Investors Weigh In On Brainstorm Cell Therapeutics

A hedge fund recently bought a new stake in Brainstorm Cell Therapeutics stock. Kingswood Wealth Advisors LLC purchased a new stake in Brainstorm Cell Therapeutics Inc. (NASDAQ:BCLI) in the first quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The firm purchased 81,050 shares of the biotechnology company’s stock, valued at approximately $46,000. Kingswood Wealth Advisors LLC owned approximately 0.12% of Brainstorm Cell Therapeutics at the end of the most recent reporting period. Hedge funds and other institutional investors own 14.33% of the company’s stock.

Brainstorm Cell Therapeutics Company Profile

Brainstorm Cell Therapeutics Inc, a biotechnology company, engages in the development and commercialization of autologous cellular therapies for the treatment of neurodegenerative diseases. The company, through its NurOwn proprietary cell therapy platform, leverages cell culture methods to induce autologous bone marrow-derived mesenchymal stem cells to secrete high levels of neurotrophic factors, modulate neuroinflammatory and neurodegenerative disease processes, promote neuronal survival, and enhance neurological function.